(in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
---|---|---|---|---|
Current assets | ||||
Cash | $55.55 | $37.22 | $69.55 | $18.39 |
Short term investments | $306.56 | $339.06 | $323.4 | $117.3 |
Net receivables | ||||
Inventory | ||||
Total current assets | $367.23 | $381.3 | $399.37 | $149.47 |
Long term investments | ||||
Property, plant & equipment | $1.13 | $1.2 | $1.27 | $1.35 |
Goodwill & intangible assets | ||||
Total noncurrent assets | $1.26 | $1.36 | $1.32 | $1.43 |
Total investments | $306.56 | $339.06 | $323.4 | $117.3 |
Total assets | $368.49 | $382.66 | $400.69 | $150.9 |
Current liabilities | ||||
Accounts payable | $7.51 | $5.71 | $5.61 | $3.8 |
Deferred revenue | ||||
Short long term debt | $0.32 | $0.32 | $0.31 | $0.31 |
Total current liabilities | $19.14 | $13.4 | $13.48 | $15.65 |
Long term debt | $0.94 | $1.02 | $1.1 | $1.18 |
Total noncurrent liabilities | $0.94 | $1.02 | $1.1 | $1.18 |
Total debt | $1.26 | $1.34 | $1.41 | $1.49 |
Total liabilities | $20.07 | $14.42 | $14.58 | $16.83 |
Shareholders' equity | ||||
Retained earnings | -$377.94 | -$353.34 | -$330.81 | -$311.58 |
Other shareholder equity | -$0.39 | -$0.91 | -$1.04 | -$0.62 |
Total shareholder equity | $348.42 | $368.24 | $386.12 | $134.06 |
(in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
---|---|---|---|---|
Current assets | ||||
Cash | $55.55 | $36.63 | $26.37 | $29.1 |
Short term investments | $306.56 | $118.85 | $175.73 | $219.27 |
Net receivables | ||||
Inventory | ||||
Total current assets | $367.23 | $167.04 | $210.53 | $256.1 |
Long term investments | ||||
Property, plant & equipment | $1.13 | $1.42 | $0.03 | $0.3 |
Goodwill & intangible assets | ||||
Total noncurrent assets | $1.26 | $1.49 | $0.13 | $0.4 |
Total investments | $306.56 | $118.85 | $175.73 | $219.27 |
Total assets | $368.49 | $168.53 | $210.66 | $256.5 |
Current liabilities | ||||
Accounts payable | $7.51 | $8.53 | $1.44 | $4 |
Deferred revenue | ||||
Short long term debt | $0.32 | $0.3 | $0.03 | $0.33 |
Total current liabilities | $19.14 | $21.95 | $8.78 | $12.1 |
Long term debt | $0.94 | $1.26 | $0.03 | |
Total noncurrent liabilities | $0.94 | $1.26 | $0.03 | |
Total debt | $1.26 | $1.56 | $0.03 | $0.36 |
Total liabilities | $20.07 | $23.21 | $8.78 | $12.2 |
Shareholders' equity | ||||
Retained earnings | -$377.94 | -$292.05 | -$223.18 | -$168.2 |
Other shareholder equity | -$0.39 | -$1.1 | -$0.55 | -$0.1 |
Total shareholder equity | $348.42 | $145.32 | $201.88 | $244.34 |
(in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
---|---|---|---|---|
Revenue | ||||
Total revenue | ||||
Cost of revenue | ||||
Gross Profit | ||||
Operating activities | ||||
Research & development | $20.5 | $18.38 | $13.92 | $11.01 |
Selling, general & administrative | $8.78 | $8.89 | $9.82 | $9.53 |
Total operating expenses | $29.29 | $27.27 | $23.74 | $20.54 |
Operating income | -$29.29 | -$27.27 | -$23.74 | -$20.54 |
Income from continuing operations | ||||
EBIT | -$24.61 | -$22.53 | -$19.23 | -$19.53 |
Income tax expense | ||||
Interest expense | ||||
Net income | ||||
Net income | -$24.61 | -$22.53 | -$19.23 | -$19.53 |
Income (for common shares) | -$24.61 | -$22.53 | -$19.23 | -$19.53 |
(in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
---|---|---|---|---|
Revenue | ||||
Total revenue | ||||
Cost of revenue | ||||
Gross Profit | ||||
Operating activities | ||||
Research & development | $63.81 | $54.23 | $44.98 | $31.93 |
Selling, general & administrative | $37.02 | $16.12 | $10.7 | $10.73 |
Total operating expenses | $100.83 | $70.36 | $55.68 | $42.66 |
Operating income | -$100.83 | -$70.36 | -$55.68 | -$42.66 |
Income from continuing operations | ||||
EBIT | -$85.89 | -$68.87 | -$54.99 | -$39.49 |
Income tax expense | ||||
Interest expense | ||||
Net income | ||||
Net income | -$85.89 | -$68.87 | -$54.99 | -$39.49 |
Income (for common shares) | -$85.89 | -$68.87 | -$54.99 | -$39.49 |
(in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
---|---|---|---|---|
Net income | -$24.61 | -$22.53 | -$19.23 | -$19.53 |
Operating activities | ||||
Depreciation | $0.07 | $0.07 | $0.07 | $0.07 |
Business acquisitions & disposals | ||||
Stock-based compensation | $4.08 | $4.48 | $4.62 | $3.57 |
Total cash flows from operations | -$17.64 | -$19.66 | -$11.44 | -$24.64 |
Investing activities | ||||
Capital expenditures | ||||
Investments | $35.73 | -$12.53 | -$204.48 | $2.2 |
Total cash flows from investing | $35.73 | -$12.53 | -$204.48 | $2.2 |
Financing activities | ||||
Dividends paid | ||||
Sale and purchase of stock | $0.19 | -$0.07 | $272.45 | $5.93 |
Net borrowings | ||||
Total cash flows from financing | $0.19 | -$0.07 | $267.08 | $4.18 |
Effect of exchange rate | $0.05 | -$0.07 | -$0 | -$0.01 |
Change in cash and equivalents | $18.28 | -$32.27 | $51.16 | -$18.26 |
(in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
---|---|---|---|---|
Net income | -$85.89 | -$68.87 | -$54.99 | -$39.49 |
Operating activities | ||||
Depreciation | $0.29 | $0.29 | $0.3 | $0.28 |
Business acquisitions & disposals | ||||
Stock-based compensation | $16.75 | $8.67 | $6.1 | $5.82 |
Total cash flows from operations | -$73.38 | -$48.4 | -$47.59 | -$21.78 |
Investing activities | ||||
Capital expenditures | ||||
Investments | -$179.09 | $54.75 | $37.96 | $41.57 |
Total cash flows from investing | -$179.09 | $54.75 | $37.96 | $41.57 |
Financing activities | ||||
Dividends paid | ||||
Sale and purchase of stock | $278.5 | $5.72 | $7.63 | $1.27 |
Net borrowings | ||||
Total cash flows from financing | $271.38 | $4.16 | $6.88 | $0.95 |
Effect of exchange rate | -$0.03 | -$0.26 | ||
Change in cash and equivalents | $18.91 | $10.52 | -$2.75 | $20.74 |
Viking (VKTX) Up 17% on Encouraging Oral Obesity Drug Data
Zacks via Yahoo Finance
27 Mar 2024
|
Viking Therapeutics’ oral weight-loss drug results lauded by analysts
Market Watch
27 Mar 2024
|
Viking Therapeutics stock gains on data for weight loss drug
Seeking Alpha
26 Mar 2024
|
Viking Therapeutic stock up 20% on oral weight-loss drug trial data
Invezz
26 Mar 2024
|
Viking Therapeutics reports positive phase 1 obesity drug trial results By Investing.com
Investing.com
26 Mar 2024
|
S&P 500 Turns Lower in Final 30 Minutes of Trading: Markets Wrap
Bloomberg via Yahoo Finance
26 Mar 2024
|
30 Biggest Biotechnology Companies in the World
Insider Monkey via Yahoo Finance
17 Mar 2024
|
Madrigal Pharma surges after drug wins first approval for fatty liver disease NASH
Reuters
15 Mar 2024
|
12 Most Profitable Biotech Stocks To Invest In
Insider Monkey via Yahoo Finance
14 Mar 2024
|
Biotech Rally Gets $100 Billion M&A Lift With More Deals to Come
Bloomberg via Yahoo Finance
14 Mar 2024
|
Market cap | $8.21B |
---|---|
Enterprise value | $8.16B |
Shares outstanding | 100.11M |
Revenue | $0.00 |
---|---|
EBITDA | -$85.60M |
EBIT | -$85.89M |
Net Income | -$85.89M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
P/E ratio | -95.57 |
---|---|
EV/Sales | N/A |
EV/EBITDA | -95.27 |
EV/EBIT | -94.94 |
P/S ratio | N/A |
P/B ratio | 23.54 |
Book/Share | 3.48 |
Cash/Share | 0.55 |
EPS | -$0.86 |
---|---|
ROA | -26.37% |
ROE | -27.78% |
Debt/Equity | 0.06 |
---|---|
Net debt/EBITDA | 0.41 |
Current ratio | 19.19 |
Quick ratio | 19.19 |